Home >> WEBINARS >> Homologous recombination deficiency and BRCA testing in ovarian and breast cancer

Homologous recombination deficiency and BRCA testing in ovarian and breast cancer

Print Friendly, PDF & Email

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Webinar presenters:
Dana Chase, MD, FACOG, Assistant Professor, Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, Arizona, Creighton University School of Medicine at St. Joseph’s Hospital, Omaha, Nebraska

Michelle Shiller, DO, MSPT, Co-Medical Director, Cancer Genetics, Pathologists Biomedical Laboratories/Baylor University Medical Center, Dallas, Texas

Tabetha Sundin, PhD, HCLD(ABB), MB(ASCP)CM, Scientific Director, Molecular Diagnostics and Serology, Sentara Healthcare
Norfolk, Virginia

The presenters discuss the role of BRCA1/2 mutations in homologous recombination deficiency and carcinogenesis, homologous recombination deficiency as a marker of treatment sensitivity, the testing process for homologous recombination deficiency and BRCA mutations, and the role of BRCA testing in ovarian and breast cancer.

This on-demand webinar originally broadcast on October 23, 2018.

CAP TODAY does not endorse any of the products or services named within.
©2018 AstraZeneca. All rights reserved. US-24014 Last Updated 10/18

x

Check Also

Current and emerging biomarkers: science, technologies, and practicalities

Webinar presenter Tabetha Sundin, PhD, HCLD, MB, discusses the crucial role pathologists play in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies. This webinar will empower you to understand the biology behind current and emerging immuno-oncology biomarkers. This on-demand webinar originally broadcast on October 3, 2018.

X